TNFRSF17 and Miyoshi myopathy: B cell maturation antigen (BCMA) is a member of the tumor necrosis factor receptor superfamily, expressed in MM cells, while normal plasma cells and mature B cells exhibit low or no expression, making it the primary target for CAR-T cell therapy in MM patients [12].